New drug cocktail shows promise for tough lung cancer
NCT ID NCT04958811
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 29 times
Summary
This study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with advanced non-squamous non-small-cell lung cancer that has already been treated. The goal is to see if this mix can shrink tumors or slow the disease. About 29 adults with specific genetic profiles are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.